Texas Yale Capital Corp. Has $963,000 Position in Bristol-Myers Squibb Co (BMY)

Texas Yale Capital Corp. lowered its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.2% during the fourth quarter, Holdings Channel reports. The fund owned 16,475 shares of the biopharmaceutical company’s stock after selling 375 shares during the period. Texas Yale Capital Corp.’s holdings in Bristol-Myers Squibb were worth $963,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in BMY. BlackRock Institutional Trust Company N.A. raised its stake in Bristol-Myers Squibb by 5.7% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 46,977,248 shares of the biopharmaceutical company’s stock valued at $2,533,013,000 after buying an additional 2,517,496 shares during the last quarter. State Street Corp raised its stake in Bristol-Myers Squibb by 3.8% in the fourth quarter. State Street Corp now owns 67,670,322 shares of the biopharmaceutical company’s stock valued at $3,954,652,000 after buying an additional 2,470,257 shares during the last quarter. Asset Management One Co. Ltd. raised its stake in Bristol-Myers Squibb by 428.0% in the fourth quarter. Asset Management One Co. Ltd. now owns 2,896,609 shares of the biopharmaceutical company’s stock valued at $169,379,000 after buying an additional 2,347,997 shares during the last quarter. UBS Asset Management Americas Inc. raised its stake in Bristol-Myers Squibb by 33.0% in the third quarter. UBS Asset Management Americas Inc. now owns 5,507,903 shares of the biopharmaceutical company’s stock valued at $296,986,000 after buying an additional 1,365,926 shares during the last quarter. Finally, Montag & Caldwell LLC raised its stake in Bristol-Myers Squibb by 118.5% in the third quarter. Montag & Caldwell LLC now owns 2,465,569 shares of the biopharmaceutical company’s stock valued at $132,943,000 after buying an additional 1,337,101 shares during the last quarter. 69.67% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Co (NYSE:BMY) opened at 56.41 on Tuesday. Bristol-Myers Squibb Co has a 52 week low of $46.01 and a 52 week high of $77.12. The firm has a market cap of $94.36 billion, a P/E ratio of 21.29 and a beta of 1.00. The company’s 50 day moving average is $54.35 and its 200-day moving average is $54.88.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, January 26th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.67 by $0.04. The company earned $5.24 billion during the quarter, compared to analyst estimates of $5.14 billion. Bristol-Myers Squibb had a net margin of 22.94% and a return on equity of 31.39%. The firm’s revenue for the quarter was up 22.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.38 EPS. Equities analysts expect that Bristol-Myers Squibb Co will post $2.82 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Friday, April 7th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Wednesday, April 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.77%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 58.87%.

Your IP Address:

BMY has been the topic of a number of research analyst reports. Cowen and Company set a $85.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Thursday, December 1st. Jefferies Group LLC reissued a “buy” rating and issued a $69.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, January 20th. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $56.28 target price on the stock. in a research report on Monday, March 13th. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Monday, January 16th. Finally, William Blair reissued an “ourperform” rating on shares of Bristol-Myers Squibb in a research report on Friday, January 20th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $61.61.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 92,405 shares of Bristol-Myers Squibb stock in a transaction on Monday, March 6th. The shares were sold at an average price of $57.02, for a total value of $5,268,933.10. Following the transaction, the executive vice president now owns 488,063 shares in the company, valued at approximately $27,829,352.26. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II purchased 12,000 shares of the firm’s stock in a transaction on Monday, February 27th. The stock was bought at an average price of $56.77 per share, for a total transaction of $681,240.00. Following the acquisition, the director now owns 12,000 shares in the company, valued at $681,240. The disclosure for this purchase can be found here. 0.24% of the stock is owned by company insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Teen Girls Barred from United Airlines Flight for Wearing Leggings
Teen Girls Barred from United Airlines Flight for Wearing Leggings
Fuel Shortage in Venezuela Growing Worse
Fuel Shortage in Venezuela Growing Worse
FedEx Comes Up Short on Earnings
FedEx Comes Up Short on Earnings
Brazil Looks to Calm Fears Over Export and Sale of Meat
Brazil Looks to Calm Fears Over Export and Sale of Meat
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram


Leave a Reply

© 2006-2017 Ticker Report. Google+.